Notoginsenoside R1 alleviates acetaminophen-induced acute liver injury by activating protective autophagy through MAPK/mTOR pathway modulation, reducing hepatocyte death and oxidative damage.
| Evidence tier | C Animal in vivo |
| Study type | 4 - Animal Study |
| Model system | Mouse |
| Journal | The American Journal of Chinese Medicine |
| Year | 2026 |
| Peer reviewed | Yes |
| Source | DOI 10.1142/S0192415X26500576 · PMID 42459050 |
Notoginsenoside R1 (NGR1), a bioactive saponin from Panax notoginseng, was investigated in acetaminophen-induced acute liver injury (AILI). NGR1 treatment activated autophagy via modulation of the MAPK/mTOR pathway, reducing hepatocyte apoptosis and oxidative stress, and attenuating liver injury in mouse models and hepatocyte cultures.
| Intervention | Notoginsenoside R1 |
| Target | MAPK/mTOR pathway; autophagy |
| Model | Mouse |
| Effect | NGR1 suppresses mTOR to activate autophagy, reducing APAP-induced hepatocyte apoptosis and liver injury |